Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Advanced Magnetics seeks expanded Feridex use:

This article was originally published in Clinica

Executive Summary

Advanced Magnetics has submitted a supplemental new drug application (sNDA) to the US FDA to expand the indications of its Feridex IV MRI contrast agent. The product is currently cleared to aid in the detection of liver lesions, but the Cambridge, Massachusetts company seeks approval to use the agent for characterising the lesions as benign or metastatic. In addition, the company would like a more convenient, rapid infusion, dosing regimen.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT069490

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel